William J. Gradishar

31.4k total citations · 6 hit papers
355 papers, 13.2k citations indexed

About

William J. Gradishar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, William J. Gradishar has authored 355 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 260 papers in Oncology, 144 papers in Pulmonary and Respiratory Medicine and 141 papers in Cancer Research. Recurrent topics in William J. Gradishar's work include Cancer Treatment and Pharmacology (118 papers), HER2/EGFR in Cancer Research (108 papers) and Breast Cancer Treatment Studies (98 papers). William J. Gradishar is often cited by papers focused on Cancer Treatment and Pharmacology (118 papers), HER2/EGFR in Cancer Research (108 papers) and Breast Cancer Treatment Studies (98 papers). William J. Gradishar collaborates with scholars based in United States, Italy and Spain. William J. Gradishar's co-authors include Paul Bhar, Neil Desai, Sergei Tjulandin, Joyce O’Shaughnessy, Michael Hawkins, Heather Shaw, Neville Davidson, Ricardo Costa, Hyo S. Han and Cesar A. Santa‐Maria and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

William J. Gradishar

337 papers receiving 12.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

2005 1.6k citations William J. Gradishar et al. Journal of Clinical Oncology profile →
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1991 1.1k citations William J. Gradishar et al. profile →
Albumin-bound paclitaxel: a next-generation taxane

2006 545 citations William J. Gradishar profile →
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

2008 378 citations William J. Gradishar et al. Journal of Clinical Oncology profile →
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Denise A. Yardley, William J. Gradishar et al. Journal of Clinical Oncology profile →
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

2018 337 citations Ricardo Costa, William J. Gradishar et al. profile →

Peers

Countries citing papers authored by William J. Gradishar

Since Specialization

Citations

This map shows the geographic impact of William J. Gradishar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. Gradishar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. Gradishar more than expected).

Fields of papers citing papers by William J. Gradishar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. Gradishar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. Gradishar. The network helps show where William J. Gradishar may publish in the future.

Co-authorship network of co-authors of William J. Gradishar

This figure shows the co-authorship network connecting the top 25 collaborators of William J. Gradishar. A scholar is included among the top collaborators of William J. Gradishar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William J. Gradishar. William J. Gradishar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulation tumor cell isolation and enrichment technologies 2025 ·International review of cell and molecular biology ·Youbin Zhang, David Scholten, Wenan Qiang, (unknown), William J. Gradishar, Shana O. Kelley, Huiping Liu	0
2	Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity 2025 ·Clinical Cancer Research ·Andrew A. Davis, (unknown), Ian S. Hagemann, Amir Behdad, (unknown), Lorenzo Gerratana, Elizabeth Mauer, Ami N. Shah, Paolo D’Amico, Lisa Flaum, Carolina Reduzzi, (unknown), William J. Gradishar, (unknown), Calvin Chao, Massimo Cristofanilli	0
3	Systemic Therapy in Breast Cancer 2024 ·American Society of Clinical Oncology Educational Book ·Chiara Corti, (unknown), (unknown), Rebecca Shatsky, Ana C. Garrido-Castro, William J. Gradishar	6
4	Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA 2024 ·Clinical Cancer Research ·(unknown), (unknown), Lorenzo Gerratana, Andrew A. Davis, Paolo D’Amico, Akhil Chawla, Saya Jacob, Youbin Zhang, Jianhua Jiao, Weijun Qin, Carolina Reduzzi, Lisa Flaum, Ami N. Shah, William J. Gradishar	2
5	Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis 2023 ·JCO Precision Oncology ·Lorenzo Gerratana, Andrew A. Davis, (unknown), Carolina Reduzzi, Katherine Clifton, (unknown), (unknown), Ami N. Shah, (unknown), Charles S. Dai, Paolo D’Amico, Firas Wehbe, Arielle J. Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, X. Cynthia, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli	7
6	Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer 2023 ·Clinical Cancer Research ·Elena Shagisultanova, William J. Gradishar, (unknown), Pavani Chalasani, Andrew Brenner, Alison Stopeck, (unknown), Dexiang Gao, (unknown), José Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges	8
7	Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity 2023 ·Science Advances ·Ziyi Fu, Siqi Chen, Yueming Zhu, (unknown), Ping Xie, (unknown), (unknown), (unknown), Yifan Xue, Xinghua Lu, Xinxin Song, Massimo Cristofanilli, William J. Gradishar, Kevin Kalinsky, Yongmei Yin, Bin Zhang, Yong Wan	18
8	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Saya Jacob, Andrew A. Davis, Lorenzo Gerratana, (unknown), Ami N. Shah, Firas Wehbe, (unknown), Qiang Zhang, Lisa Flaum, Kalliopi P. Siziopikou, Leonidas C. Platanias, William J. Gradishar, Amir Behdad, Aditya Bardia, Massimo Cristofanilli	35
9	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, (unknown), Simon Waters, Sara A. Hurvitz, Beverly Moy, Sung‐Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald Wallweber, Judith D. Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge	15
10	Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial 2021 ·JNCI Journal of the National Cancer Institute ·Lynne I. Wagner, Janet A. Tooze, Daniel L. Hall, Beverly J. Levine, Jennifer L. Beaumont, Jennifer Duffecy, David Victorson, William J. Gradishar, Joseph W. Leach, Thomas J. Saphner, Keren Sturtz, Mary Lou Smith, Frank J. Penedo, David C. Mohr, David Cella	46
11	A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial 2021 ·JMIR Research Protocols ·Siobhan M. Phillips, (unknown), Whitney A. Welch, Lisa Auster‐Gussman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jungwha Lee, Bonnie Spring, William J. Gradishar	9
12	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials 2020 ·Clinical Cancer Research ·Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Aman U. Budzar, J.F.R. Robertson, William J. Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen Johnston, Stephen Chia	100
13	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis 2019 ·Clinical Cancer Research ·Melinda L. Telli, Charles C. Chu, Sunil Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William J. Gradishar, Vered Stearns, Roisín M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy E. Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson	23
14	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer 2017 ·Clinical Cancer Research ·Giovanna Rossi, Zhaomei Mu, Alfred Rademaker, (unknown), (unknown), Ricardo Costa, Rebecca J. Nagy, Vittorina Zagonel, Timothy Taxter, Amir Behdad, Firas Wehbe, Leonidas C. Platanias, William J. Gradishar, Massimo Cristofanilli	106
15	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy 2015 ·Clinical Cancer Research ·William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan D. Novosiadly, Amélie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska	54
16	Oncology Fellows' Career Plans, Expectations, and Well-Being: Do Fellows Know What They Are Getting Into? 2014 ·Journal of Clinical Oncology ·Tait D. Shanafelt, Marilyn Raymond, Leora Horn, (unknown), Frances A. Collichio, Helen K. Chew, Michael P. Kosty, Daniel Satele, Jeff A. Sloan, William J. Gradishar	46
17	Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. 2014 ·PubMed ·William J. Gradishar, Christopher Twelves, Hope S. Rugo	1
18	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 2013 ·Clinical Cancer Research ·George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, (unknown), Oumar Sy, Linda T. Vahdat, Javier Cortés	36
19	Bisphosphonates and Osteonecrosis of the Jaw 2007 ·Journal watch ·William J. Gradishar	35
20	NCCN Task Force Report: Adjuvant Therapy for Breast Cancer 2006 ·Journal of the National Comprehensive Cancer Network ·Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles L. Loprinzi, Eleftherios P. Mamounas, Edith A. Perez, Kathleen I. Pritchard, Peter M. Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, (unknown)	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact